News from Thursday, October 5, 2023
Articles
Podcast: ICER’s Faux Updates
(10/5, Healthcare Policy Pop) comments “John O’Brien, President and CEO of the National Pharmaceutical Council, weighs in on ICER’s latest update that we are calling a ‘faux update’...” Full
Atropos Health Unveils AI Chatbot to Accelerate Real-World Data-Based Evidence Generation for Docs
(10/5, Anastassia Gliadkovskaya, Fierce Healthcare) reports “...Leveraging generative AI, the system helps non-technical users query real-world clinical data and get publication-grade results in minutes, the startup said. The Geneva OS can be installed on an organization’s cloud environment while maintaining security and HIPAA compliance. ‘We can now generate evidence for every individual patient extremely quickly and at scale,’ Brigham Hyde, co-founder and CEO of Atropos, told Fierce Healthcare.” Full
Making The Promise Of Value-Based Care Meaningful To Consumers
(10/5, Jocelyn Frye, Frederick Isasi and Emily Stewart, Health Affairs Forefront) comments “...Here, we share our vision for how individuals, patients, and families can be best served by accountable care models that center on individual needs and preferences. Meaningful, equity-focused, value-based care is a promising and necessary alternative to fee-for-service medicine. We also call for action to increase provider uptake of value-based care models and engage patients and communities in their development, implementation, and evaluation.” Full
Press Releases
Second International Consensus Report - Clinical Translation of Precision Diabetes Medicine
(10/4, Diabetologia Press Release) “...‘Diabetes recommendations often focus on what works well for the average person. However, because diabetes is an incredibly heterogeneous disease, few people are Mr or Mrs “average” and one-size-fits-all approaches fail many people in need. Precision medicine seeks to address this major problem,’ says Professor Paul Franks, of Lund University, Sweden, who chaired the Consensus Report.” Full
Journals
Second International Consensus Report on Gaps and Opportunities for the Clinical Translation of Precision Diabetes Medicine
Deirdre K. Tobias, et al.
October 5, 2023, Nature Medicine
Treatment Effect Heterogeneity Following Type 2 Diabetes Treatment with GLP1-Receptor Agonists and SGLT2-Inhibitors: A Systematic Review
Katherine G. Young, et al.
October 5, 2023, Communications Medicine